GLP-1(9-37) UltraPure

Store at -25 ~ -15 °C and shipped at ≤0℃.

Product description

Semaglutide intermediate 29 peptide (also known as Semaglutide 29 peptide main chain, Intermediate P29 or GLP-1 (9-37)) is a key intermediate in the synthesis of semaglutide active pharmaceutical ingredient (API). Semaglutide is a human glucagon-like peptide-1 analog that stimulates glucose-dependent insulin secretion by mediating GLP-1 receptor. It is used for blood glucose control in adult patients with type 2 diabetes. The long-term mechanism of semaglutide results from a structural modification wherein a C18 fatty acid chain is conjugated to the lysine residue at position 26. The modification increases molecular weight and enhances albumin binding affinity by 5-6-fold thereby reducing renal clearance and metabolic degradation to prolong in vivo half-life.

The semaglutide intermediate 29 peptide is produced via genetic engineering fermentation, yielding high-purity product. This freeze-dried powder is obtained through enzymatic digestion, chromatography purification, and lyophilization of the recombinant semaglutide precursor expressed inEscherichia coli.

Product Application

Used for the production ofsemaglutide.

Transportation and storage.

Store at -25 ~ -15 °C and shipped at ≤0℃ .

Product characteristics